Overview

Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L)

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2026-12-31

Target enrollment:

Participant gender:

Summary

This phase II MATCH treatment trial tests how well BVD-523FB (ulixertinib) works in treating patients with cancer that has certain genetic changes. BVD-523FB (ulixertinib) is used in patients whose cancer has a mutated (changed) form of a gene called BRAF. It is in a class of medications called kinase inhibitors. It works by blocking the action of proteins that signal cancer cells to multiply. This helps slow or stop the spread of cancer cells.

Phase:

PHASE2

Details

Lead Sponsor:

National Cancer Institute (NCI)

Treatments:

Biopsy
Magnetic Resonance Spectroscopy
Nuclear Medicine Department, Hospital
Specimen Handling
ulixertinib